VIDEO: Speaker outlines real-world advantages, risks of Port Delivery System
NEW YORK — David Eichenbaum, MD, discusses insights gained from real-world cases using the Port Delivery System with ranibizumab in this presentation from OSN New York Retina.
Eichenbaum provides an overview of the steps involved in the implantation of the device, now known as Susvimo (Genentech), and outlines the benefits and possible adverse events associated with its use.
“PDS is the first commercially available sustained-release treatment for common retinal disease,” he said. “Reintroduction after recall will be a critical time, and we have to work together with each other and the manufacturer if this is going to be a viable solution to our patients.”
Collapse
Eichenbaum D. Real world experience with the Port Delivery System. Presented at: OSN New York and OSN New York Retina; Nov. 11-Nov. 13, 2022; New York.
Read more about